Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epinephrine + budesonide is a combination therapy consisting of the sympathomimetic agent epinephrine and the glucocorticoid budesonide, typically administered via nebulization. Epinephrine acts rapidly to induce vasoconstriction of the laryngeal mucosa through alpha-adrenergic receptors, thereby reducing edema and airway obstruction. Budesonide provides a more sustained anti-inflammatory effect by inhibiting the recruitment of inflammatory cells and the release of mediators. This combination is primarily utilized for the management of acute laryngeal edema, including post-extubation edema and croup, to improve airway patency and reduce the need for re-intubation. Clinical protocols and research involving this combination have been notably advanced by institutions such as The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of TCM).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epinephrine + budesonide.